Literature DB >> 24022461

A quantitative assay to study protein:DNA interactions, discover transcriptional regulators of gene expression, and identify novel anti-tumor agents.

Karen F Underwood1, Maria T Mochin, Jessica L Brusgard, Moran Choe, Avi Gnatt, Antonino Passaniti.   

Abstract

Many DNA-binding assays such as electrophoretic mobility shift assays (EMSA), chemiluminescent assays, chromatin immunoprecipitation (ChIP)-based assays, and multiwell-based assays are used to measure transcription factor activity. However, these assays are nonquantitative, lack specificity, may involve the use of radiolabeled oligonucleotides, and may not be adaptable for the screening of inhibitors of DNA binding. On the other hand, using a quantitative DNA-binding enzyme-linked immunosorbent assay (D-ELISA) assay, we demonstrate nuclear protein interactions with DNA using the RUNX2 transcription factor that depend on specific association with consensus DNA-binding sequences present on biotin-labeled oligonucleotides. Preparation of cells, extraction of nuclear protein, and design of double stranded oligonucleotides are described. Avidin-coated 96-well plates are fixed with alkaline buffer and incubated with nuclear proteins in nucleotide blocking buffer. Following extensive washing of the plates, specific primary antibody and secondary antibody incubations are followed by the addition of horseradish peroxidase substrate and development of the colorimetric reaction. Stop reaction mode or continuous kinetic monitoring were used to quantitatively measure protein interaction with DNA. We discuss appropriate specificity controls, including treatment with non-specific IgG or without protein or primary antibody. Applications of the assay are described including its utility in drug screening and representative positive and negative results are discussed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24022461      PMCID: PMC3857129          DOI: 10.3791/50512

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  9 in total

1.  Electrophoretic mobility shift assay (EMSA) for detecting protein-nucleic acid interactions.

Authors:  Lance M Hellman; Michael G Fried
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

2.  TransLISA, a novel quantitative, nonradioactive assay for transcription factor DNA-binding analyses.

Authors:  Kristiina A Vuori; Johanna K Ahlskog; Lea Sistonen; Mikko Nikinmaa
Journal:  FEBS J       Date:  2009-12       Impact factor: 5.542

3.  Genomics. ENCODE project writes eulogy for junk DNA.

Authors:  Elizabeth Pennisi
Journal:  Science       Date:  2012-09-07       Impact factor: 47.728

4.  Development of a sensitive multi-well colorimetric assay for active NFkappaB.

Authors:  P Renard; I Ernest; A Houbion; M Art; H Le Calvez; M Raes; J Remacle
Journal:  Nucleic Acids Res       Date:  2001-02-15       Impact factor: 16.971

5.  Regulation of RUNX2 transcription factor-DNA interactions and cell proliferation by vitamin D3 (cholecalciferol) prohormone activity.

Authors:  Karen F Underwood; David R D'Souza; Maria Mochin-Peters; Adam D Pierce; Sravya Kommineni; Moran Choe; Jessica Bennett; Averell Gnatt; Bahru Habtemariam; Alexander D MacKerell; Antonino Passaniti
Journal:  J Bone Miner Res       Date:  2012-04       Impact factor: 6.741

6.  Hyperglycemia regulates RUNX2 activation and cellular wound healing through the aldose reductase polyol pathway.

Authors:  David R D'Souza; Maryann M Salib; Jessica Bennett; Maria Mochin-Peters; Kaushal Asrani; Simeon E Goldblum; Keli J Renoud; Paul Shapiro; Antonino Passaniti
Journal:  J Biol Chem       Date:  2009-04-21       Impact factor: 5.157

7.  High-throughput detection of nuclear factor-kappaB activity using a sensitive oligo-based chemiluminescent enzyme-linked immunosorbent assay.

Authors:  Nupur Bhattacharya; Antonio Sarno; Irina S Idler; Marita Führer; Thorsten Zenz; Hartmut Döhner; Stephan Stilgenbauer; Daniel Mertens
Journal:  Int J Cancer       Date:  2010-07-15       Impact factor: 7.396

Review 8.  DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition.

Authors:  Yves Pommier
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

9.  A functional analysis of the CREB signaling pathway using HaloCHIP-chip and high throughput reporter assays.

Authors:  Danette D Hartzell; Nathan D Trinklein; Jacqui Mendez; Nancy Murphy; Shelley F Aldred; Keith Wood; Marjeta Urh
Journal:  BMC Genomics       Date:  2009-10-27       Impact factor: 3.969

  9 in total
  7 in total

1.  A rapid and sensitive high-throughput screening method to identify compounds targeting protein-nucleic acids interactions.

Authors:  Nicole Alonso; Roboan Guillen; Jeremy W Chambers; Fenfei Leng
Journal:  Nucleic Acids Res       Date:  2015-02-04       Impact factor: 16.971

2.  Hyperglycemia and redox status regulate RUNX2 DNA-binding and an angiogenic phenotype in endothelial cells.

Authors:  Maria T Mochin; Karen F Underwood; Brandon Cooper; John C McLenithan; Adam D Pierce; Cesar Nalvarte; Jack Arbiser; Anna I Karlsson; Alexander R Moise; Jackob Moskovitz; Antonino Passaniti
Journal:  Microvasc Res       Date:  2014-10-02       Impact factor: 3.514

3.  Using yeast to determine the functional consequences of mutations in the human p53 tumor suppressor gene: An introductory course-based undergraduate research experience in molecular and cell biology.

Authors:  Daria S Hekmat-Scafe; Sara E Brownell; Patricia Chandler Seawell; Shyamala Malladi; Jamie F Conklin Imam; Veena Singla; Nicole Bradon; Martha S Cyert; Tim Stearns
Journal:  Biochem Mol Biol Educ       Date:  2016-11-22       Impact factor: 1.160

4.  RUNX2 and TAZ-dependent signaling pathways regulate soluble E-Cadherin levels and tumorsphere formation in breast cancer cells.

Authors:  Jessica L Brusgard; Moran Choe; Saranya Chumsri; Keli Renoud; Alexander D MacKerell; Marius Sudol; Antonino Passaniti
Journal:  Oncotarget       Date:  2015-09-29

5.  Characterization of CADD522, a small molecule that inhibits RUNX2-DNA binding and exhibits antitumor activity.

Authors:  Myoung Sook Kim; Ramkishore Gernapudi; Eun Yong Choi; Rena G Lapidus; Antonino Passaniti
Journal:  Oncotarget       Date:  2017-08-10

6.  Repression of viral gene expression and replication by the unfolded protein response effector XBP1u.

Authors:  Florian Hinte; Eelco van Anken; Boaz Tirosh; Wolfram Brune
Journal:  Elife       Date:  2020-02-17       Impact factor: 8.140

7.  Targeting breast cancer metabolism with a novel inhibitor of mitochondrial ATP synthesis.

Authors:  Myoung Sook Kim; Ramkishore Gernapudi; Yessenia Cedeño Cedeño; Brian M Polster; Ramon Martinez; Paul Shapiro; Santosh Kesari; Elmar Nurmemmedov; Antonino Passaniti
Journal:  Oncotarget       Date:  2020-10-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.